Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2003
03/27/2003CA2460334A1 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003CA2460120A1 Compositions and methods for the diagnosis and treatment of tumor
03/27/2003CA2460076A1 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
03/27/2003CA2458720A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/26/2003EP1295892A1 Antisense molecules and method of controlling expression of gene function by using the same
03/26/2003EP1295611A1 Oligonucleotide-transferring preparations
03/26/2003EP1295610A2 Crystals of free and antibiotic complexed large ribosomal subunits
03/26/2003EP1295601A1 Pharmaceutical composition based on a non-steroid anti-inflammatory agent
03/26/2003EP1295600A2 Medicament based on gestagens for dermal application
03/26/2003EP1295598A1 Pharmaceutical composition containing two active ingredients for smoking cessation
03/26/2003EP1295596A1 Systems and compounds for drug delivery to interstitial regions of the myocardium
03/26/2003EP1295595A1 Tablet rapidly disintegrating in mouth and process for producing the same
03/26/2003EP1295538A2 Encapsulated locust bean fibre with improved properties, process for making it and use thereof
03/26/2003EP1294949A2 Human tumor necrosis factor delta and epsilon
03/26/2003EP1294938A2 Cell-binding nucleic acid molecules (aptamers)
03/26/2003EP1294920A2 Deesterified pectins, processes for producing such pectins, and stabilized acidic liquid systems comprising the same
03/26/2003EP1294808A2 Fast cure film forming formulation
03/26/2003EP1294770A1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
03/26/2003EP1294769A1 Antibodies that immunospecifically bind to blys
03/26/2003EP1294746A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
03/26/2003EP1294740A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use
03/26/2003EP1294646A2 Devices and method for production of traceable immunizing drinking water, other liquids and gas
03/26/2003EP1294513A1 Site-specific, covalent bioconjugation of proteins
03/26/2003EP1294479A1 Method for producing capsules containing an active ingredient and having an ultra-thin coating
03/26/2003EP1294439A2 Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system
03/26/2003EP1294413A1 Sprayable wound care compositions
03/26/2003EP1294409A2 Membrane-permeant peptide complexes for medical imaging
03/26/2003EP1294405A2 Prodrug compounds cleavable by thimet oligopeptidase
03/26/2003EP1294404A2 Prodrug compounds with an oligopeptide having an isoleucine residue
03/26/2003EP1294403A2 Tripeptide prodrug compounds
03/26/2003EP1294402A2 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
03/26/2003EP1294376A2 Medicament for combating respiratory depression
03/26/2003EP1294375A2 Method of treatment of seborrheic dermatitis
03/26/2003EP1294369A1 NOVEL FORMULATIONS OF $g(a)-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
03/26/2003EP1294368A1 Management of snoring by oral administration of dimethyl sulfone
03/26/2003EP1294365A2 Cytotoxic agents comprising single-stranded and/or looped dna
03/26/2003EP1294364A1 Stable gabapentin having ph within a controlled range
03/26/2003EP1294363A1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
03/26/2003EP1294361A2 Compositions and methods to improve the oral absorption of antimicrobial agents
03/26/2003EP1294359A1 Process for preparing and harvesting crystalline particles
03/26/2003EP1294358A2 Wet milling process
03/26/2003EP1294357A1 Bioavailable dosage form of isotretinoin
03/26/2003EP1198226B1 Mesalazine controlled release oral pharmaceutical compositions
03/26/2003EP1181010A4 Pharmaceutical chewing gum formulations
03/26/2003EP1173215A4 Over-coated chewing gum formulations
03/26/2003EP1156786B1 Orally dispersible tablet with low friability and method for preparing same
03/26/2003EP1150701A4 Homing pro-apoptotic conjugates and methods of using same
03/26/2003EP1140960A4 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
03/26/2003EP1140195B1 Oil-in-water emulsion exhibiting a protective action against damages to human organs resulting from peroxidation, and the production and use thereof
03/26/2003EP1126848B1 Plastics container containing stabilised drug formulations
03/26/2003EP1077703B1 Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
03/26/2003EP1049452B1 Reduced lipid flowable cosmetic or dermatological preparations
03/26/2003EP1042339B1 Carbohydrates, useful in solid delivery systems
03/26/2003EP1041969B1 Novel pharmaceutical compositions of uridine triphosphate
03/26/2003EP1032373B1 Drug delivery systems utilizing liquid crystal structures
03/26/2003EP0941070B1 Lozenge for the modified releasing of active substances in the gastrointestinal tract
03/26/2003EP0848621B1 Wound treatment composition
03/26/2003EP0847240B1 Novel embolizing compositions
03/26/2003EP0831867B1 Collagen-based delivery matrix
03/26/2003EP0772436B1 Incorporation of biologically active molecules into bioactive glasses
03/26/2003EP0740528B1 Gas microspheres for topical and subcutaneous application
03/26/2003EP0670716B1 Tastemasked pharmaceutical materials
03/26/2003EP0431135B1 Particle-mediated transformation of animal somatic cells
03/26/2003EP0431128B1 Vector coding for self-assembled, defective, non-self-propagating viral particles
03/26/2003CN1406255A Cosmetic agent
03/26/2003CN1406249A Enhancing the circulating half-life of antibody-based fusion proteins
03/26/2003CN1406140A Nano capsule encapsulation system and method
03/26/2003CN1406137A Caspase activated prodrugs therapy
03/26/2003CN1406136A Novel antibody with specificity for colon cancer
03/26/2003CN1406130A Veterinary compositions for the treatment of parasitic diseases
03/26/2003CN1406126A New sustained release oral formulations
03/26/2003CN1406125A Method for transdermal or intradermal delivery of molecules
03/26/2003CN1406124A Nasally administrable cyclic peptide compositions
03/26/2003CN1406112A Composition for intestinal delivery
03/26/2003CN1405127A Nitrogenous group conversion method
03/26/2003CN1404833A 药物组合物 The pharmaceutical composition of
03/26/2003CN1103782C Mono-pegylated MGDF polypeptide
03/26/2003CN1103643C Film coatings and film coating compositions based on dextrin
03/26/2003CN1103604C Iron-containing nano particles with double coating and their use in diagnosis and therapy
03/26/2003CN1103587C Compressible enzyme powder
03/26/2003CN1103586C Sucrose ester C20-28 alcohol formulations
03/26/2003CA2405378A1 Stable taurolidine electrolyte solutions
03/25/2003USRE38046 (delayed type sensitivity) DTH-Effector cells are printed with carbohydrate antigens; antitumor
03/25/2003US6538124 Polypeptide variants
03/25/2003US6538106 Compositions and methods for treating infections using analogues of indolicidin
03/25/2003US6538104 Stabilization of cardiac troponin I subunits and complexes
03/25/2003US6538030 Treating radiation fibrosis
03/25/2003US6538020 Paclitaxel formulation
03/25/2003US6538019 Produce emulsions containing a material that are insoluble or that have low solubility with respect to water and oil in a high concentration, so as to obtain emulsions which can be preserved for a long period of time. More specifically,
03/25/2003US6538011 Composition for the antidandruff treatment of the hair and scalp based on an antidandruff active principle and on a hydroxy acid
03/25/2003US6537985 Antibiotic formulation and a method of making this formulation
03/25/2003US6537979 Water-insoluble derivatives of hyaluronic acid crosslinked with a biscarbodiimide
03/25/2003US6537968 Treatment of an individual suffering from lupus erythematosus utilizing a serine protease inhibitor. The treatment includes the use of a corticosteroid that is administered separately or in combination. The serine proteases preferred are alpha
03/25/2003US6537814 Compositions and methods for altering the biodistribution of biological agents
03/25/2003US6537813 Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
03/25/2003US6537764 Method of identifying inhibitors of C—C chemokine receptor 3
03/25/2003US6537592 Extracts of kava-kava
03/25/2003US6537590 Solution and the method of making the same for the treatment of osteoarthritis
03/25/2003US6537586 Apparatus and method for preparing microparticles
03/25/2003US6537585 Methods and compositions for treating solid tumors
1 ... 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 ... 1712